- Home
- FORA vs ENTX Comparison
FORA vs ENTX Comparison
Compare FORA & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORA
- ENTX
- Stock Information
- Founded
- FORA 2014
- ENTX 2010
- Country
- FORA United States
- ENTX Israel
- Employees
- FORA N/A
- ENTX N/A
- Industry
- FORA Computer Software: Prepackaged Software
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FORA Technology
- ENTX Health Care
- Exchange
- FORA Nasdaq
- ENTX Nasdaq
- Market Cap
- FORA 62.7M
- ENTX 69.6M
- IPO Year
- FORA N/A
- ENTX 2018
- Fundamental
- Price
- FORA $1.96
- ENTX $1.79
- Analyst Decision
- FORA Strong Buy
- ENTX Strong Buy
- Analyst Count
- FORA 1
- ENTX 1
- Target Price
- FORA $5.00
- ENTX $10.00
- AVG Volume (30 Days)
- FORA 30.3K
- ENTX 30.9K
- Earning Date
- FORA 05-13-2025
- ENTX 05-09-2025
- Dividend Yield
- FORA N/A
- ENTX N/A
- EPS Growth
- FORA N/A
- ENTX N/A
- EPS
- FORA N/A
- ENTX N/A
- Revenue
- FORA $20,153,263.00
- ENTX $181,000.00
- Revenue This Year
- FORA $13.31
- ENTX N/A
- Revenue Next Year
- FORA N/A
- ENTX N/A
- P/E Ratio
- FORA N/A
- ENTX N/A
- Revenue Growth
- FORA N/A
- ENTX N/A
- 52 Week Low
- FORA $1.85
- ENTX $1.41
- 52 Week High
- FORA $4.03
- ENTX $2.79
- Technical
- Relative Strength Index (RSI)
- FORA 46.06
- ENTX 49.59
- Support Level
- FORA $1.90
- ENTX $1.50
- Resistance Level
- FORA $2.08
- ENTX $1.84
- Average True Range (ATR)
- FORA 0.12
- ENTX 0.11
- MACD
- FORA 0.02
- ENTX 0.03
- Stochastic Oscillator
- FORA 41.02
- ENTX 85.50
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.